The Interaction Between the Expression of Proliferative Biomarkers and Clinical Characteristics in Breast Cancer

Publish Year: 1397
نوع سند: مقاله ژورنالی
زبان: English
View: 287

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MCIJO-2-2_004

تاریخ نمایه سازی: 28 بهمن 1399

Abstract:

Introduction: Proliferation of cancer cells and the potential of metastasis depend on the activity of different biomarkers such as proliferative ones. Proliferative biomarkers including ki-67, cyclin E1, cyclin D1, p27, and p21 were analyzed through immunohistochemistry (IHC) in previous studies. Methods: The current study aimed at investigating the utilizing role of RT-PCR in studying proliferative biomarkers including Ki-67, Cyclin E1, Cyclin D1, P27, and P21 to figure out the association between proliferative biomarkers and clinical aspects in patients with early breast cancer. One hundred and twenty-three patients with primary breast cancer were entered in the current study. Patients’ clinicopathological characteristics were obtained and also expressions of the proliferative biomarkers were investigated through RT-PCR on both cancerous and normal adjacent breast tissue. Results: It was observed that in contrast to Cyclin D and P27, expression of Ki-67, Cyclin E, and P21 were higher in tumor samples compared with normal adjacent tissue. In addition, Cyclin D was higher in ER/PR positive and HER2 negative tumors and it was also higher in greater tumor size. Similarly, Cyclin E expression was higher in greater tumor size. Furthermore, patients with higher expression of P27 experienced worse prognosis. Conclusions: Studying the proliferative biomarkers via a quantitative and automated method in Iranian patients showed that proliferative biomarkers had correlations with clinical aspects. Further studies to analyze the clinical utility of proliferative biomarkers in greater populations are warranted.

Authors

Sepideh Mansouri

Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Rezvan Esmaeili

Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Ahmad Kaviani

Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.

Mahdi Rezaei

Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Nasrin Abdoli

Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Parisa Mokhtari-Hesari

Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Leila Farahmand

Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Keivan Majidzadeh-A

Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont ...
  • 2. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 ...
  • 3. Khan AA, Abel PD, Chaudhary KS, Gulzar Z, Stamp ...
  • 4. Hu Y, Sun H, Drake J, Kittrell F, Abba ...
  • 5. Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger ...
  • 6. Murray SA, Yang S, Demicco E, Ying H, Sherr ...
  • 7. Salimi M, Mozdarani H, Majidzadeh K. Expression pattern of ...
  • PMID:2 1 8 5 0 5 4 1 ...
  • 8. Mehdipour P, Pirouzpanah S, Sarafnejad A, Atri M, Shahrestani ...
  • 9. Zhao C, Meng L, Hu H, Wang X, Shi ...
  • 10. de Azambuja E, Cardoso F, de Castro G, Jr., ...
  • 11. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp ...
  • 12. Prihantono P, Hatta M, Binekada C , Sampepajung D, ...
  • 13. Majidzadeh AK, Kaviani A, Esmaeili R, Farahmand L, Shojamoradi ...
  • 15. Yuan P, Xu B, Wang C, Zhang C, Sun ...
  • 16. Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Jesionek-Kupnicka ...
  • 17. Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh ...
  • 18. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia ...
  • 19. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene ...
  • 20. Wei CY, Tan QX, Zhu X, Qin QH, Zhu ...
  • 21. Han SH, Park KM, Bae BN, Ryu SY, Kim ...
  • 22. Oh YL, Choi JS, Song SY, Ko YH, Han ...
  • 23. O’Lone R, Frith MC, Karlsson EK, Hansen U. Genomic ...
  • 24. Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick ...
  • 25. Anim JT, John B, Abdulsathar SS, Prasad A, Saji ...
  • 26. Luhtala S, Staff S, Tanner M, Isola J. Cyclin ...
  • 27. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller ...
  • 28. Wong H, Lau S, Cheung P, Wong TT, Parker ...
  • 29. Zheng WQ, Zheng JM, Ma R, Meng FF, Ni ...
  • 30. Mirchandani D, Roses DF, Inghirami G, Zeleniuch- Jacquotte A, ...
  • 31. Niu D, Wang G, Wang X. Up-regulation of cyclin ...
  • 32. Gohring UJ, Bersch A, Becker M, Neuhaus W, Schondorf ...
  • 33. Thor AD, Liu S, Moore DH, 2nd, Edgerton SM. ...
  • 34. Iacopetta B, Grieu F, Powell B, Soong R, Mc- ...
  • 35. Weikel W, Beck T, Mitze M, Knapstein PG. Immunohistochemical ...
  • 36. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro ...
  • 37. Barbareschi M, van Tinteren H, Mauri FA, Veronese S, ...
  • 38. Leivonen M, Nordling S, Lundin J, von Boguslawski K, ...
  • 39. Barnes A, Pinder SE, Bell JA, Paish EC, Wencyk ...
  • 40. Lau R, Grimson R, Sansome C, Tornos C, Moll ...
  • 41. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti ...
  • 42. Diab SG, Yu YY, Hilsenbeck SG, Allred DC, Elledge ...
  • 43. Mathoulin-Portier MP, Viens P, Cowen D, Bertucci F, Houvenaeghel ...
  • 44. Thor AD, Liu S, Moore DH, 2nd, Shi Q, ...
  • 45. Ceccarelli C, Santini D, Chieco P, Lanciotti C, Taffurelli ...
  • 46. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski ...
  • 47. Hwang TS, Han HS, Hong YC, Lee HJ, Paik ...
  • 48. Michalides R, Hageman P, van Tinteren H, Houben L, ...
  • 49. van Diest PJ, Michalides RJ, Jannink L, van der ...
  • 50. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey ...
  • 51. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression ...
  • 52. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin ...
  • 53. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression ...
  • 54. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep ...
  • 55. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies ...
  • 56. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner ...
  • 57. Cheng CW, Liu YF, Yu JC, Wang HW, Ding ...
  • 58. Guo LL, Gao P, Wu YG, Jian WC, Hao ...
  • 59. Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza ...
  • 60. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, ...
  • 61. Somlo G, Chu P, Frankel P, Ye W, Groshen ...
  • نمایش کامل مراجع